Association between the use of levodopa/carbidopa, Alzheimer's disease biomarkers, and cognitive decline among participants in the National Alzheimer's Coordinating Center Uniform Data Set
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Zsuzsa Sárkány und 3 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Levodopa, Alzheimer Disease, Cognitive Dysfunction, Carbidopa. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Intramural NIH HHS, Horizon 2020 Framework Programme.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION This retrospective study investigates whether exposure to levodopa/carbidopa (LA/CA) medication is associated with modified Alzheimer's disease (AD) trajectories. METHODS Multivariate analysis used cerebrospinal fluid (CSF) biomarker information included in the National Alzheimer's Coordinating Center Uniform Data Set for subjects with normal cognition (NC), mild cognitive impairment (MCI), and dementia (DE). Survival analyses examined the progression to MCI/DE and death events. RESULTS LA/CA use is associated with lower levels of CSF amyloid beta, phosphorylated‐tau (p‐tau) and total‐tau. After adjusting for age, sex, and apolipoprotein E (APOE) ε4 allele presence, that effect was quantified by negative coefficients of the fitted linear mixed models: p ‐values < 0.01 in all cases except for p‐tau in the MCI subgroup ( p = 0.02). No similar effects were identified for other antiparkinsonians. Exposure to LA/CA decreased the progression from MCI to DE ( p = 0.03). DISCUSSION The identified association between LA/CA exposure, AD biomarkers, and progression deserves further investigation in controlled clinical trials. Highlights LA/CA is associated with lower levels of CSF biomarkers for AD. This effect is not observed when other antiparkinsonian drugs are used. LA/CA is also associated with delayed progression to dementia by AD patients with MCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
- IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.
- Centro de Genética Preditiva e Preventiva (CGPP), IBMC Universidade do Porto, Porto, Portugal.
- Neurology Department, Centro Hospitalar Universitário de Santo António, ULS de Santo António, Porto, Portugal.
- ICBAS School of Medicine and Biomedical Sciences, Universidade do Porto, Porto, Portugal.
ORCID-Profile: Pedro M Martins
Förderung
- NIA NIH HHS
- Intramural NIH HHS
- Horizon 2020 Framework Programme
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Sárkány, Z., Damásio, J., Macedo-Ribeiro, S., & Martins, P. M. (2025). Association between the use of levodopa/carbidopa, Alzheimer's disease biomarkers, and cognitive decline among participants in the National Alzheimer's Coordinating Center Uniform Data Set. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70213
Vancouver
Sárkány Z, Damásio J, Macedo-Ribeiro S, Martins PM. Association between the use of levodopa/carbidopa, Alzheimer's disease biomarkers, and cognitive decline among participants in the National Alzheimer's Coordinating Center Uniform Data Set. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70213
BibTeX
@article{Srkny2025,
author = {Sárkány, Zsuzsa and Damásio, Joana and Macedo-Ribeiro, Sandra and Martins, Pedro M},
title = {Association between the use of levodopa/carbidopa, Alzheimer's disease biomarkers, and cognitive decline among participants in the National Alzheimer's Coordinating Center Uniform Data Set},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70213}
}
EUVIMED